SAR 260301

Drug Profile

SAR 260301

Alternative Names: SAR260301

Latest Information Update: 21 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 05 Feb 2015 Discontinued - Phase-I for Malignant melanoma (Late-stage disease) in Canada (PO)
  • 05 Feb 2015 Discontinued - Phase-I for Lymphoma (Late-stage disease) in Canada (PO)
  • 05 Feb 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top